Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy

Aliabadi, Hamidreza Montazeri; Maranchuk, Robert A.; Kucharski, Cezary; Mahdipoor, Parvin; Hugh, Judith; Uludağ, Hasan

doi:10.1016/j.jconrel.2013.08.012

Cited by 53 publications

(52 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aliabadi et al 62 used a xenograft nu/nu nude mouse model with MDA-435 sensitive and resistance cells injected subcutaneously into the right flank of the mice. 63 This model, along with the authors’ work delivering vascular endothelial growth factor siRNA and doxorubicin to mice helped elucidate a decrease in tumor blood vessels which allowed for an increase in life span of the tumor-bearing mice.…”

Section: Animal Modelsmentioning

confidence: 99%

Tackling breast cancer chemoresistance with nano-formulated siRNA

Jones

Merkel

2016

Gene Ther

View full text Add to dashboard Cite

Breast cancer is the leading cancer diagnosed in women and the second leading cause of cancer-related deaths in women. Current limitations to standard chemotherapy in the clinic are extensively researched, including problems arising from repeated treatments with the same drugs. The phenomenon that cancer cells become resistant toward certain chemo drugs is called chemotherapy resistance. In this review, we are focusing on nanoformulation of siRNA for the fight against breast cancer chemoresistance.

show abstract

Section: Animal Modelsmentioning

confidence: 99%

Tackling breast cancer chemoresistance with nano-formulated siRNA

Jones

Merkel

2016

Gene Ther

View full text Add to dashboard Cite

show abstract

“…Treatment of tumor-bearing animals with siRNA against Mcl-1 reduces tumor volume significantly. When siRNA for silencing Ribosomal Protein S6 Kinase was co-delivered, the anti-tumor effect was enhanced in the absence of chemotherapy at the low injection dose of 1.5 µg per mouse for intratumoral delivery and 10 µg per mouse for intraperitoneal injections [49]. …”

Section: Sirna For Breast Cancer Therapymentioning

confidence: 99%

“…The levels of siRNA uptake and protein down-regulation were generally higher with a higher level of lipid substitution [85]. The lipid-substituted polymer can also be used to co-deliver siRNA simultaneously, and the resulting nanoparticles showed a more potent response in drug-resistant breast cancer models (p<0.05 vs. scrambled siRNA) [49]. …”

Section: Recent Advances In Non-viral Delivery Vectors For Sirna Imentioning

confidence: 99%

Non-viral nanocarriers for siRNA delivery in breast cancer

Zhang

Huang

2014

Journal of Controlled Release

View full text Add to dashboard Cite

Breast cancer is the most frequently diagnosed malignancy in American women. While significant progress has been made in development of modern diagnostic tools and surgical treatments, only marginal improvements have been achieved with relapsed metastatic breast cancer. Small interfering RNAs (siRNAs) mediate gene silencing of a target protein by disrupting messenger RNAs in an efficient and sequence-specific manner. One application of this technology is the knockdown of genes responsible for tumorigenesis, including those driving oncogenesis, survival, proliferation and death of cells, angiogenesis, invasion and metastasis, and resistance to treatment. Non-viral nanocarriers have attracted attention based on their potential for targeted delivery of siRNA and efficient gene silencing without toxicity. Here, we review promising, non-viral delivery strategies employing liposomes, nanoparticles and inorganic materials in breast cancer.

show abstract

“…Despite the improvements and the efficiency in early detection, chemotherapy and radiotherapy breast cancer is still at high risks [2][3][4]. Therefore, it is necessary to find a cure for this disease, a lot of scientific researches were carried out to determine a particular molecule to this treatment [5].…”

Section: Introductionmentioning

confidence: 99%